

# INDEX

- Accelerated fractionation, 115–120  
clinical studies, 116–120  
rationale, 115–116  
strategies, 116
- ACE inhibitors effects on  
radiation pneumotoxicity,  
130–134  
renal radiation injury, 134–136  
skin reactions, 133–134
- Acetylsalicylic acid, 139
- Acoustic neuromas, 288–289
- Adaptive nulling, 219–220, 227–  
228
- Adaptive phased arrays, 226–227
- Adenovirus  
gene therapy vector, 156–157,  
160–162  
oncoproteins, 174
- Adriamycin, 179
- Afterloading, high dose-rate. *See*  
High dose-rate afterloading
- Algorithms  
dose calculation, 12–15  
dose-optimization, 39, 61  
inverse-planning, 39  
leaf sequencing, 39–43  
plan-optimization, 19–21  
simulated annealing, 20  
verification testing, 26–27
- Alpha Cradle immobilization form,  
4
- Americium-241 (<sup>241</sup>Am)  
pelvic malignancies, 195  
shielding, 194
- Amorphous silicon imagers, 92
- Androgen suppressive therapy, 264
- Angiography and arteriovenous  
malformations, 285–286
- Angioma, cavernous, 287
- Angioplasty, brachytherapy and,  
204
- Angiotensin II receptor antagonists,  
136–138
- Anisotropy  
interstitial brachytherapy  
sources, 196–197  
intracavitary brachytherapy  
sources, 195–196
- Antibodies, monoclonal, 237–238,  
273
- Antifibrotics, 145
- Antihypertensives, 135–136
- Antiinflammatory drugs, 138–140
- Antioxidant enzymes, 144–145
- Apoptosis, 106, 179–181, 181–  
183, 183–185
- Applicators, hyperthermia  
adaptive focusing arrays, 219–  
220  
adaptive phased arrays, 226–  
227  
AMC four-waveguide array, 226  
BSD-2000/Sigma 60 annular  
array, 221–225  
capacitive, 227–229  
conformal and planar arrays,  
216–219  
current sheet, 214–215, 219  
lens, 215–216  
low-frequency, 215  
Utrecht coaxial TEM array, 225–  
226
- Arachidonic acid, 141
- Array applicators  
adaptive focusing, 219–220  
adaptive phased, 226–227  
AMC four-waveguide, 226  
BSD-2000/Sigma 60 annular,  
221–225  
conformal and planar, 216–219  
Utrecht coaxial TEM, 225–226
- Arterial stenosis and brachytherapy,  
204
- Arteriovenous malformations  
(AVM), 285–288
- Asialoglycoprotein receptor, 158
- Aspirin, 140
- Ataxia telangiectasia, 176
- Automated radiation therapy. *See*  
CCRT (computer-controlled  
radiation therapy)
- Autonomously replicating  
sequences, 170
- Beam Imaging System (BIS), 46
- Beam modulation techniques. *See*  
*also* Intensity modulation  
radiotherapy (IMRT)
- Beam modulation techniques, 35–  
48
- Beam penumbra, 61
- Beam's-eye view (BEV), 2, 10, 13,  
248
- Beamview portal imager, 74–75
- Bentley-Milan algorithm, 12
- Bioballistics, 156, 158
- Bladder cancer  
hyperfractionation, 115  
hyperthermia, 222
- Bladder shielding, brachytherapy  
and, 194
- Bleomycin, 179
- Blood pressure, radiation  
nephropathy and, 135–138
- Bloom syndrome, 176
- Bone marrow transplantation,  
135–138, 144
- Brachytherapy, 191–204  
cost, 192–193  
dose distribution nonuniformity,  
46  
esophageal cancer, 202–203  
gynecological malignancies,  
198–200  
high dose-rate afterloading,  
193–194, 263  
interstitial, 196–197  
intracavitary, 195–196  
lung carcinoma, 202  
nonmalignancy uses, 204  
ocular melanoma, 201–202  
permanent implants, 197–198,  
262–263  
prostate cancer, 200–201,  
262–263  
radionuclide characteristics,  
191–193  
sarcoma of the extremity, 203  
shielding, 194–195
- Brain metastases, 291–294
- Breast cancer  
accelerated fractionation, 118  
Adriamycin, 170  
cyclin D1, 172  
drug resistance, 180  
tissue-specific gene expression,  
159–160
- BSD-2000/Sigma 60 annular array,  
221–225
- Burkitt's lymphoma  
accelerated fractionation, 116  
p53 gene and, 180

- Caffeine, 178, 180
- Camptothecin, 179–180
- Capacitive arrays, 227–229
- Captopril, 130–134
  - antifibrotic activity, 132–133
  - endothelial function, 131–132
  - radiation nephropathy and, 135–138
  - radiation pneumotoxicity and, 130–134
  - skin reactions and, 133–134
- Carboplatin, 224–225
- CCRT (computer-controlled radiation therapy), 21–25, 49–66
  - clinical use of, 63–64
  - collision-detection sensors, 65
  - electronic portal imaging, 63
  - intensity-modulated treatments, 57–60, 61–63
  - multileaf collimator, 51–54
  - multisegment treatments, automated, 54–57, 60–61
  - multisegment treatments, semiautomated, 57, 60–61
  - quality assurance, 64–66
  - safety, 64–66
  - treatment planning, 60–63
- Cell cycle, 169–186
  - apoptosis, 183–185
  - CLDRI (continuous low dose-rate irradiation), 198
  - G1 delay and drug therapies, 182–183
  - G2 delay and drug therapies, 178–180
  - G1 delay and irradiation, 180–182
  - G2 delay and irradiation, 177–178
  - phases, 169–171
  - redistribution, 110
  - regulation of, 171–174
  - response to DNA damage, 174–177
  - as therapeutic target, 185–186
- Cellular repair, cell cycle and, 175–177
- Cervical cancer
  - brachytherapy, 194, 199–200
  - hyperthermia, 222
  - shielding, 194
- Cesium-137 (<sup>137</sup>Cs)
  - brachytherapy, 191–192
  - HDR afterloading, 193
  - intracavitary brachytherapy, 195
- CHART (Continuous Hyperfractionated Accelerated Radio Therapy) schedule, 116–118, 122
- Chemotherapy. *See also specific chemotherapeutic agent*
  - cell cycle phase use table, 184
  - drug resistance, 180, 272–273
  - G1 cell cycle delay, 182–183
  - G2 cell cycle delay, 178–180
  - gene therapy and, 161
- Cisplatin, 179, 183, 224
- Clarkson irregular field algorithm, 12–15
- Clinac Control Computer, 37–38
- Clinical target volume (CTV), 5–10, 274
- Clinical trials
  - pharmacologic modification of normal tissue injury, 145–146
  - prophylactic vs treatment, 145–146
  - toxicity reduction vs radiation dose escalation, 146
- CNS radiation injury. *See also* Spinal cord injury
  - antiinflammatory drug therapy, 139
  - hyperfractionation, 113
- Coaxial TEM array, 225–226
- Cobalt-60 (<sup>60</sup>Co)
  - endometrial carcinoma, 199
  - HDR afterloading, 193
- Cobalt-Gamma Knife procedure, 283
- Collimator. *See* Multileaf collimator
- Collision-detection sensors, 65
- Colon shielding, brachytherapy and, 194
- Colorectal carcinoma
  - gene therapy, 161
  - radioimmunotherapy, 237
- Colpostats, 194
- Compton scattering, 78, 194
- Computed tomography (CT)
  - acoustic neuromas, 288–289
  - brachytherapy planning, 195
  - cone beam, 91
  - conformal radiation therapy (CRT), 3D and, 1–15, 23
  - electronic portal imaging and, 91
  - image registration, 276–278
  - prostate definition, 253–255
  - SPECT, 5
  - stereotactic radiosurgery, 283
  - thermal modeling and, 229–231
- Computer-controlled radiation therapy. *See* CCRT (computer-controlled radiation therapy)
- Conformal arrays, 216–219
- Conformal radiation therapy (CRT), 3D, 1–29
  - beam design and field shaping, 10–11
  - beam's-eye view (BEV), 274–275
  - computer-controlled (CCRT), 21–25, 49–66
  - computer optimization, 19–21
  - data management, 25–26
  - defined, 271
  - dose calculation, 12–15
  - dose displays, 15–17
  - dose volume histograms, 248–249, 275–276
  - electronic portal imaging and, 91
  - future directions, 28–29
  - ICRU Report 50, 5–10
  - image registration, 276–278
  - imaging, 3–5
  - immobilization, 3–4
  - implementation, 278–279
  - infinite margin concept, 249–250
  - intensity-modulation (IMRT), 35–48, 57–63, 259–261
  - local-regional control and, 271–273
  - NCI (National Cancer Institute) contracts, 2–3
  - normal tissue complication probability modeling, 17–19
  - plan optimization, interactive, 19
  - positioning, patient, 3–4
  - prostate cancer and, 247–261
  - quality assurance, 26–28
  - surgery compared, 269
  - target delineation, 273–274
  - tumor control probability modeling, 17–19
  - volume dose specification, 5–10
- Constructive interference, 218
- Continuous low dose-rate irradiation (CLDRI), 197–198
- Convolution kernels, 15
- Corticosteroids, 138–140
- Costs
  - brachytherapy, 192–193
  - electronic portal imaging, 72
  - implementing new technology, 247–248
  - proton beam irradiation, 262
- Critical volume tolerance method, 256

- CT. *See* Computed tomography (CT)
- Current sheet applicator, 214–215
- Cyclin box, 171
- Cyclin-dependent kinase inhibitors, 173
- Cyclin-dependent kinases, 171–173, 184
- Cyclins, 170–173, 177–183  
 cyclin box, 171  
 dependent kinases, 171–173, 184  
 destruction box, 172  
 kinase inhibitors, 173  
 malignancy association, 172
- Cyclooxygenase inhibitors, 140
- Cytokines and gene therapy, 153–163
- Cytoskeleton, 171
- Dartmouth array, 217
- Data storage and portal imaging, 72, 79, 84
- Deconvolution optimization, 194
- Deep hyperthermia, 221–229  
 adaptive phase arrays, 226–227  
 AMC four-wave guide array, 226  
 BSD-2000/Sigma 60 annular array, 221–225  
 capacitive applicators, 227–229  
 ingestible temperature sensor, 235–236  
 Utrecht coaxial TEM array, 225–226
- Dermal necrosis, 133–134, 142
- Destruction box, 172
- Dexamethasone, 138–140
- Display, dose, 15–17
- DNA damage, cell cycle response to, 174–177
- Dose calculation, 12–15  
 Bentley-Milan algorithm, 12  
 Clarkson irregular field algorithm, 12–15  
 convolution/superposition algorithms, 15  
 EPL (effective path-length) algorithm, 12  
 Monte Carlo simulations, 15
- Dose escalation, 121–122  
 clinical trials, 146  
 prostate radiotherapy, 256–259
- Dose-optimization algorithm, 39
- Dose volume histograms, 7, 9–10, 15–18, 248–249, 275–276  
 prostate cancer, 249, 251–252, 257, 259
- Dosimetry  
 of brachytherapy sources, 195–197  
 electronic portal, 89–90  
 Doxorubicin, 179, 183  
 DRRs (digitally reconstructed radiographs), 5, 10–11, 69–70
- Drug resistance, 180, 272–273
- Dynamic therapy, 90–91
- Dynamic Transmission Factor, 42–43
- Dynamic Wedges, 38, 59–60, 578
- Echo-planar imaging, 234
- Eicosanoids, 138, 140–141
- Electrical impedance tomography, 234–235
- Electromagnetic hyperthermia. *See* Hyperthermia
- Electron beam imaging, 91
- Electronic portal imaging, 28, 69–93  
 acceptance, 80  
 advantages/disadvantages, 70–72  
 analysis tools, 78  
 applications, 84–93  
 calibration, 81  
 CCRT and, 63  
 commissioning, 80–82  
 cone beam CT, 91  
 conformal radiation therapy (CRT), 3D, 91  
 costs, 72  
 detector arrays, 74–77  
 display, image, 78  
 electron beam imaging, 91  
 error detection, 87  
 as exit dosimeter, 89–90  
 features, system, 77–80  
 field of view, 77  
 as film replacement, 84  
 fluoroscopic systems, 74–77  
 future development of, 90–92  
 image manipulation, 78–79  
 image quality, 70–73, 81  
 image registration, 84–87  
 implementation, clinical, 82–84  
 intensity-modulated radiation therapy, 90–91  
 MLC verification, 89  
 networking, 80, 84  
 organ motion, 88  
 quality assurance, 82, 90  
 safety, 77, 80  
 setup verification, 70, 73, 87–89  
 silicon imagers, amorphous, 92  
 software, 81–82  
 systems, 73–80  
 terminology, 69–70  
 tomotherapy, 92  
 treatment interventional verification, 87  
 treatment planning system integration, 91
- Electroporation, 156, 158
- Endometrial carcinoma. *See* Uterine cancer
- Endothelium  
 captopril and function, 131–132  
 glomerular, injury of, 137–138
- Enucleation, 202
- Epidermal growth factor, 183
- EPL (effective path-length)  
 algorithm, 12
- Esophageal cancer, brachytherapy of, 202–203
- Estramustine, 179, 264
- Etoposide, 179, 181
- Exit dosimeter, 89–90
- Fatty acids, polyunsaturated. *See* Polyunsaturated fatty acids
- Fibrosis, 145  
 antiinflammatory drug therapy and, 139  
 antioxidant enzymes and, 144–145  
 captopril effect on, 132–133
- Field matching, 89
- Field shaping, 10–11
- Finite element analysis  
 electrical impedance tomography, 235  
 hyperthermia treatment planning, 232–233
- Flat-panel imaging, 92
- Flow cytometry, 110
- Fluorouracil, 264
- Four-waveguide array, 226
- Fractionation, 101–123  
 accelerated, 115–120  
 acoustic neuromas, 289  
 biologic effect of varying, 102–112  
 defined, 101  
 dose escalation potential, 121–122  
 hyperfractionation, 112–115  
 optimal choice, 120–121  
 patient immobilization, 3  
 redistribution, 110  
 reoxygenation, 110

- repair capacity and kinetics, 102–106
- repopulation, cell, 106–110
- time-dose formulae, 110–112
- Functional radiosurgery, 284, 294–295
- GADD, 175, 181
- Gamma Knife radiosurgery, 283–284
  - arteriovenous malformations, 285
  - brain metastases, 291–292
  - cost-benefit analysis, 293–294
  - pituitary adenomas, 291
- Ganciclovir, 156, 160–161
- Gene therapy, 153–163
  - administration route, 158
  - components, 153–155
  - delivery systems, 156–158
  - preclinical studies, 161–162
  - radioprotection of tissue, 162–163
  - target cells, 160–161
  - therapeutic genes, 155–156
  - transcriptional regulation, 158–160
- Geometric optimization, HDR afterloading, 194
- Glioma, malignant, 294
  - estramustine, 179
  - gene therapy, 156–157, 161–161
  - radiosurgery, 284–285, 294
- Gross tumor volume (GTV), 6–9
- Growth arrest and DNA damage inducible (GADD) genes, 175
- Growth factors, cellular, 169, 172, 183
- Gynecologic malignancies, brachytherapy of, 198–200
- Half-life, radionuclide, 192
- Half-value layer (HVL) thicknesses, 192
- HDR afterloading. *See* High dose-rate afterloading
- Head and neck cancer
  - fractionation, 113–120
  - local control and metastasis, 271
  - time-to-recurrence, 108
- Heaviside step function, 40
- Hemangioblastoma, 291
- Herpes simplex virus (HSV), 156–157, 159–161
- High dose-rate afterloading
  - brachytherapy, 193–194, 199–200, 202–203
  - esophageal cancer, 202–203
  - gynecological malignancies, 199–200
  - lung cancer, 202
  - prostate cancer, 263
- Hormonal therapy and prostate cancer, 264
- Hyperfractionation
  - clinical studies, 113–115
  - defined, 112
  - rationale, 112–113
- Hypertension, radiation nephropathy and, 135–138
- Hyperthermia, 213–239
  - deep, 221–229
  - external irradiation combined, 237–238
  - internal radiation combined, 237
  - modeling, 229–233
  - noninvasive, 233–236
  - superficial, 213–221
- Hypoxia, tumor, 185
- Ibuprofen, 140
- ICRU (International Commission on Radiation Units and Measurements), 5–10
- Ilmofoosine, 180
- Image registration, 84–87, 276–278
  - automated, 86–87
  - computer-aided, 85–86
  - qualitative, 84–85
- Image segmentation software, 5–6
- Immobilization
  - conformal radiation therapy (CRT), 3D, 3–4
  - portal imaging evaluation of, 88
  - setup errors and, 252
- IMRT. *See* Intensity modulation radiotherapy (IMRT)
- Indomethacin, 140
- Infinite margin concept, 249–250
- Ingestible temperature sensor, 235–236
- Intensity modulation radiotherapy (IMRT), 21–24, 35–38, 57–63
  - CCRT and, 57–63
  - dose distribution, 14
  - electronic portal imaging and, 90–91
  - prostate cancer, 259–261
- Interleukin-3 (IL-3), 185
- Interstitial brachytherapy, 196–197
- Interstitial hyperthermia, 221
- Intracavitary brachytherapy, 195–196
- Intravascular brachytherapy, 204
- Inverse-planning algorithm, 39, 47–48
- Iodine-125 (<sup>125</sup>I)
  - brachytherapy, 192
  - interstitial brachytherapy, 196
  - ocular melanoma, 202
  - permanent implants, 198
  - prostate cancer, 200–201
- Iodine-131 (<sup>131</sup>I)
  - radioimmunotherapy, 237–238
- Iridium-192 (<sup>192</sup>Ir)
  - brachytherapy, 192
  - dose distributed anisotropy, 195–196
  - endometrial carcinoma, 199
  - HDR afterloading, 193
  - interstitial brachytherapy, 197
  - prostate cancer, 201
  - sarcoma of the extremity, 203
- Isocenter displacement errors, 253
- Isoeffect curve, 110–111
- Isoeffect formula, 111–112, 121
- Isoeffective doses, 103–104
- Kidneys and radiation injury, 134–138
- Kinases, 169–173, 176–178, 180–184
  - cyclin-dependent, 171–173, 184
  - inhibitors, cyclin-dependent, 173, 181
- Ku protein, 176–177
- Labthermics array, 217–220
- Las Vegas phantom, 81
- Leaf sequencing algorithm, 39–40
- LED matrix phantom, 224–225
- Lens applicators, 215–216
- Leukotrienes, 140–141
- Li-Fraumeni syndrome, 176, 185
- Ligand conjugates, 158
- Linac (linear accelerator)
  - radiosurgery, 284
  - brain metastases, 292
  - pituitary adenomas, 291
- Linear accelerator and MLC integration, 38
- Linoleic acid, 141–142
- Liposomes, 156–158, 162
- Liver and gene therapy, 158
- Lungs
  - cancer brachytherapy, 202
  - radiation-induced injury

- treatment, 130–134, 139–140, 144
- Magnetic resonance angiography (MRA), 286
- Magnetic resonance imaging (MRI)  
acoustic neuromas, 288–289  
arteriovenous malformations, 285–286  
brachytherapy planning, 195  
conformal radiation therapy (CRT), 3D and, 5, 28  
image registration, 276–278  
noninvasive thermometry, 233–234  
prostate definition, 253–255  
stereotactic radiosurgery, 283  
thermal modeling and, 229–230
- Mast cells, 133
- Matrix phantom, LED, 224–225
- Maturation promoting factor, 170–171
- Meclofenamate, 139
- Melanoma  
brachytherapy for ocular, 201–202  
gene therapy, 157  
prostaglandins and, 183
- Meningiomas, 290–291
- Microtherm array, 217–220
- Microwave hyperthermia. *See* Hyperthermia
- Mitotic delay, 106
- MLC. *See* Multileaf collimator
- Modeling  
hyperthermia treatment, 229–233  
normal tissue complications, 17–19  
tumor control, 17–19
- Modulation Scale Factor, 41–43
- Monoclonal antibodies, 237–238, 273
- Monte Carlo simulations, 15, 28, 195
- Moving gap technique, 54, 58
- MRI. *See* Magnetic resonance imaging (MRI)
- Multidrug resistance, 272–273
- Multileaf collimator (MLC), 21–25, 35–48, 50–54  
CCRT and, 50–54, 57–66  
clearance, 51  
dynamic, 35–48, 57–59  
electronic portal verification, 89  
leaf overtravel, 54  
leaf sequencing algorithms, 39–43
- leaf shape, 51–53  
leaf speed, 54  
leaf transmission, 51  
leaf width, 53–54  
slit, 59  
Varian, 35–38, 46, 50–52, 56
- Myc, 175–178, 185
- Myeloid leukemia, 180
- Myelopathy, radiation. *See* Spinal cord injury
- NCI (National Cancer Institute)  
3D CRT data objects, 26  
research contracts, 2–3
- NEMA (National Electrical Manufacturers Association), 26
- Neoadjuvant androgen suppressive therapy (NAST), 264
- Nephropathy, radiation, 134–138  
ACE inhibitors, 134–136  
angiotensin II receptor antagonists, 136–138  
antiinflammatory drugs and, 138–139  
endothelial cell injury, 137–138
- Neuropathy, radiation, 288, 290–291
- Nitric oxide, 137
- Noninvasive thermometry, 233–236  
electrical impedance, 234–235  
ingestible temperature sensor, 235–236  
magnetic resonance-based, 233–234
- Nonsteroidal antiinflammatory drugs (NSAIDs), 138–140
- Normal tissue complication probability  
modeling, 17–18  
prostate cancer, 255–259
- Normal tissue injury. *See* Tissue injury, pharmacological modification of
- Numerical modeling and hyperthermia treatment, 229–233
- Objective function, 19–20
- Ocular melanoma, brachytherapy, 201–202
- ODI (optical distance indicator), 27
- Oncogenes, 174, 175–177, 185
- Optimization  
algorithms, 19–21  
automated computer, 19–21
- interactive, 19
- Organ motion  
electronic portal imaging, 88  
prostate cancer therapy and, 249, 252–253, 258, 261–262
- Ovarian carcinoma, hyperthermia and, 224–225
- Palladium-103 (<sup>103</sup>Pd)  
brachytherapy, 192  
interstitial brachytherapy, 197  
permanent implants, 198  
prostate cancer, 200–201
- Papillomavirus, 174
- Pelvic malignancies, hyperthermia and, 221–226
- Pentoxifylline, 132, 143–144, 180
- PET (positron emission tomography), 5
- p53 gene, 174–176, 179–186
- Phosphatases, 169, 171
- Phosphorylation and cell cycle, 169–174, 177
- Pirfenidone, 145
- Piroxicam, 140
- Pituitary adenomas, 291
- Planar arrays, 216–219
- Planning target volume (PTV), 6–10, 60–62, 274
- Plan optimization, interactive, 19
- Plasminogen activator, 132
- Pneumotoxicity, radiation  
antiinflammatory drugs and, 139–140  
captopril and, 130–134
- Polyunsaturated fatty acids, 140–143
- Portal imaging. *See* Electronic portal imaging
- PortalVision imager, 74–75, 78, 81
- Positioning, patient  
conformal radiation therapy (CRT), 3D, 3–4  
image registration, 84–87  
portal imaging, 69–71, 73, 84–87
- Positron emission tomography (PET), 5
- pRb (Retinoblastoma gene product), 172–174, 181–182
- Prednisolone, 140
- Prodrug-converting enzymes, 156
- Programmed cell death. *See* Apoptosis
- Promoters, 158–160, 170
- Prostacyclin, 131–132, 140–141

- Prostaglandins, 140–141
- Prostate cancer, 247–264  
 accelerated fractionation, 120  
 brachytherapy, 200–201, 262–263  
 CCRT application, 58, 63–64  
 dose escalation, 256–259  
 dose volume histograms, 249, 251–252, 257, 259  
 hormonal therapy, 264  
 hyperthermia, 223  
 intensity modulated radiotherapy (IMRT), 43–47, 58, 259–261  
 local control and metastasis, 271  
 normal tissue complication probability, 255–259  
 proton beam irradiation, 262  
 PSA (prostate-specific antigen), 255, 264  
 spectroscopy, MR, 263–264  
 target definition, 253–255  
 taxol, 179  
 tissue-specific gene expression, 159  
 treatment techniques, 250–251  
 tumor control probabilities, 255–259  
 verification imaging, 261–262
- Prostate-specific antigen (PSA), 200–201
- Proton beam irradiation, 262, 284–285
- PSA (prostate-specific antigen), 255, 264
- Puromycin, 179
- Radiation-inducible promoter, 159–160
- Radiation therapy. *See also specific therapy*  
 dose delivery, inadequate, 270–272  
 failure causes, 270–273  
 local and systemic disease control, 271–273  
 surgery compared, 269
- Radiation Therapy Oncology Group (RTOG)  
 data exchange specifications, 25  
 dose-escalation protocol, 113  
 pentoxifylline trial, 144  
 quality assurance criteria, 214, 279
- Radiographs, digitally reconstructed. *See* DRRs (digitally reconstructed radiographs)
- Radioimmunotherapy, 237–238
- Radioisotopes. *See specific radioisotope*
- Radioprotection of tissue, gene therapy and, 153–155, 162–163
- Radiosensitivity  
 brachytherapy and, 204  
 cell cycle and, 106–107, 110  
 gene therapy and, 153–163  
 pentoxifylline, 144  
 p53 gene and, 180–182  
 protein kinase C inhibitors, 158
- Radiosurgery, 283–295  
 acoustic neuromas, 288–289  
 arteriovenous malformations (AVM), 285–288  
 benign tumors, 291  
 brain metastases, 291–294  
 clinical results, 285–295  
 dosimetry, 283  
 equipment, 283–284  
 functional, 284, 294–295  
 glioma, malignant, 294  
 meningiomas, 290–291  
 radiobiological considerations, 284–285  
 trigeminal neuralgia, 294–295
- Radium-226 (<sup>226</sup>Ra)  
 brachytherapy, 191–192
- Radon-222 (<sup>222</sup>Rn)  
 brachytherapy, 191–192
- Ras, 176–178
- Rectum  
 cancer hyperthermia, 222, 224  
 prostate radiotherapy and, 249, 252, 259
- Redistribution, 110, 113
- Registration, image. *See* Image registration
- Renin-angiotensin system, 137
- Reoxygenation, 110
- Repair capacity and kinetics, cellular, 102–106
- Repair half-time, 103, 104–105
- Replication, cellular. *See* Cell cycle
- Replicons, 170, 176
- Repopulation, cell, 106–110  
 normal tissue, 108  
 tumors, 108–110
- Restriction point, cell cycle, 169, 171, 173
- Retinoblastoma gene product (pRb), 172–174, 181–182
- Retroviruses, 156–157
- Rhizotomy, 295
- Room-view display, 10, 13–14
- RTOG. *See* Radiation Therapy Oncology Group (RTOG)
- Samarium-145 (<sup>145</sup>Sm)  
 interstitial brachytherapy, 204
- Sarcoma of the extremity, 203
- Scanditronix, 50–51, 54–56, 63–64
- Schwannomas, 291
- Segmented Treatment Table (STT), 36–38, 56–57
- Shielding  
 brachytherapy, 194  
 of kidney with total body irradiation, 135
- Sievert's integral, 195, 203
- Silicon imagers, amorphous, 92
- Simulated annealing algorithm, 20
- Skin radiation injury  
 captopril and, 133–134  
 polyunsaturated fatty acids and, 141–142
- Software  
 electronic portal imaging, 81–82  
 image analysis, 71  
 image segmentation, 5–6  
 ultrasound image fusion, 263  
 validation tests, 27
- Specific activity, radionuclide, 192
- Spectroscopy, MR, 263–264
- SPECT (single photon emission computed tomography), 5
- Spinal cord injury  
 antiinflammatory drug therapy, 139  
 fractionation schedules and, 106, 113  
 polyunsaturated fatty acid therapy, 142–143
- Spiraling modulated beam, 35, 59
- Squamous cell carcinoma. *See also* Head and neck cancer  
 cyclins, 172  
 epidermal growth factor and, 183  
 time-to-recurrence, 108
- SRI 100 portal imager, 74–75, 78, 79, 86
- Stanford array, 217, 219
- Stenosis, arterial, 204
- Stepping source dosimetry system, 194
- Stereotactic radiosurgery. *See* Radiosurgery
- Superficial hyperthermia, 213–221  
 adaptive focusing arrays, 219–220  
 conformal and planar arrays, 216–219  
 current sheet applicators, 214–215, 219  
 interstitial and external

- combined, 221
- lens applicators, 215–216
- low-frequency applicators, 215
- Superoxide dismutase (SOD), 144–145
- Target-cell concept, 103
- Taxol, 179, 183
- Temperature sensor, ingestible, 235–236
- Tetracycline-inducible promoter, 159
- Therapeutic ratio
  - accelerated fractionation, 116
  - brachytherapy, 191
  - defined, 153
  - gene therapy, 153–155
- Theraview portal imager, 74–75, 78
- Thermometry. *See* Hyperthermia
- Thiaproline, 145
- Three-dimensional radiotherapy treatment planning (3D RTTP). *See* Conformal radiation therapy (CRT)
- Thromboxane, 132, 140–141
- Time distribution of dose. *See* Fractionation
- Time-dose formulae, 110–112
- Time-to-recurrence
  - fractionated radiotherapy and, 108–119
- Tissue injury, pharmacological modification of, 129–147
  - angiotensin II receptor antagonists, 138–140
  - antifibrotics, 145
  - antiinflammatory drugs, 138–140
  - antioxidant enzymes, 144–145
  - captopril, 130–138
  - clinical trials, 145–146
  - pentoxifylline, 143–144
  - polyunsaturated fatty acids, 140–143
- T loop, 171, 172
- Tomography. *See* Computed tomography (CT); Electrical impedance tomography
- Tomotherapy, 35, 59, 92
- Topoisomerases, DNA, 170, 179–180
- Toremifene, 180
- Total body irradiation, 135–138
- Trigeminal neuralgia, 294–295
- Tumor control probability
  - models, 17–19
  - prostate cancer, 255–259
- Tumor necrosis factor-alpha (TNF- $\alpha$ ), 154–162
- Tumor vasculature
  - gene therapy and, 158, 160
  - radiosurgery, high-dose single fraction, 284–285
- Ultrasound, transrectal, 195, 200–201
- Urethrography, 253–254
- Uterine cancer
  - brachytherapy, 199
  - hyperthermia, 222
- Utrecht coaxial TEM array, 225–226
- Varian
  - multileaf collimator, 35–38, 46, 50–52, 56
  - PortalVision, 74–75, 78, 81
- Vascular malformations, 285–288
- Vectors, gene therapy, 153–163
- Verapamil, 135
- Vestibular schwannomas, 288–289
- Vinblastine, 180
- Viruses
  - gene therapy vectors, 154–161
  - oncogenesis, 174
- Xeroderma pigmentosum, 176